Austar Lifesciences Ltd. (HK:6118)
:6118
Want to see HK:6118 full AI Analyst Report?
Total Valuation
Austar Lifesciences Ltd. has a market cap or net worth of HK$415.19M. The enterprise value is HK$423.01M.
Market CapHK$415.19M
Enterprise ValueHK$423.01M
Share Statistics
Austar Lifesciences Ltd. has 512,582,030 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding512,582,030
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Austar Lifesciences Ltd.’s return on equity (ROE) is 0.04 and return on invested capital (ROIC) is 3.06%.
Return on Equity (ROE)0.04
Return on Assets (ROA)0.02
Return on Invested Capital (ROIC)3.06%
Return on Capital Employed (ROCE)0.06
Revenue Per Employee1.06M
Profits Per Employee22.79K
Employee Count1,445
Asset Turnover0.72
Inventory Turnover4.42
Valuation Ratios
The current PE Ratio of Austar Lifesciences Ltd. is 11.8. Austar Lifesciences Ltd.’s PEG ratio is 0.11.
PE Ratio11.8
PS Ratio0.26
PB Ratio0.49
Price to Fair Value0.49
Price to FCF4.02
Price to Operating Cash Flow2.80
PEG Ratio0.11
Income Statement
In the last 12 months, Austar Lifesciences Ltd. had revenue of 1.53B and earned 33.80M in profits. Earnings per share was 0.07.
Revenue1.53B
Gross Profit293.27M
Operating Income54.15M
Pretax Income48.13M
Net Income33.80M
EBITDA73.05M
Earnings Per Share (EPS)0.07
Cash Flow
In the last 12 months, operating cash flow was 136.83M and capital expenditures -23.23M, giving a free cash flow of 113.60M billion.
Operating Cash Flow136.83M
Free Cash Flow113.60M
Free Cash Flow per Share0.22
Dividends & Yields
Austar Lifesciences Ltd. pays an annual dividend of HK$0.05, resulting in a dividend yield of ―
Dividend Per ShareHK$0.05
Dividend Yield―
Payout Ratio―
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.96
52-Week Price Change15.94%
50-Day Moving Average0.79
200-Day Moving Average0.99
Relative Strength Index (RSI)49.23
Average Volume (3m)695.30K
Important Dates
Austar Lifesciences Ltd. upcoming earnings date is Sep 1, 2026, TBA (Confirmed).
Last Earnings DateMar 26, 2026
Next Earnings DateSep 1, 2026
Ex-Dividend Date―
Financial Position
Austar Lifesciences Ltd. as a current ratio of 1.36, with Debt / Equity ratio of 41.78%
Current Ratio1.36
Quick Ratio1.12
Debt to Market Cap0.83
Net Debt to EBITDA0.92
Interest Coverage Ratio4.59
Taxes
In the past 12 months, Austar Lifesciences Ltd. has paid 15.25M in taxes.
Income Tax15.25M
Effective Tax Rate0.32
Enterprise Valuation
Austar Lifesciences Ltd. EV to EBITDA ratio is 6.40, with an EV/FCF ratio of 4.69.
EV to Sales0.31
EV to EBITDA6.40
EV to Free Cash Flow4.69
EV to Operating Cash Flow3.65
Balance Sheet
Austar Lifesciences Ltd. has HK$276.59M in cash and marketable securities with HK$343.82M in debt, giving a net cash position of -HK$67.23M billion.
Cash & Marketable SecuritiesHK$276.59M
Total DebtHK$343.82M
Net Cash-HK$67.23M
Net Cash Per Share-HK$0.13
Tangible Book Value Per ShareHK$1.53
Margins
Gross margin is 19.16%, with operating margin of 3.54%, and net profit margin of 2.21%.
Gross Margin19.16%
Operating Margin3.54%
Pretax Margin3.14%
Net Profit Margin2.21%
EBITDA Margin4.77%
EBIT Margin2.82%
Analyst Forecast
The average price target for Austar Lifesciences Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast2.17%
EPS Growth Forecast109.41%